Coming soon? A new formulation of abiraterone acetate?

In January this year we had mentioned that a company called Churchill Pharmaceuticals was developing a new “submicron” formulation of abiraterone acetate. … READ MORE …

“Active surveillance … how to do it right”

Many readers, and particularly many support group leaders and other educators, may want to read and retain a copy of this very recent article in Oncology. … READ MORE …

Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

Cancer tissue subtypes and prostate cancer prognosis

A newly published article in JAMA Oncology is asking whether there is a completely different way to look at how to classify prostate cancer tissue types and correlate such classification to responses to treatment using certainly classes of drugs. … READ MORE …

Scripps proton beam radiation therapy center files for bankruptcy

We have long been concerned that the number of proton beam radiation therapy (PBRT) centers being built here in the USA was way higher than could be justified by the real demand for such services. … READ MORE …

Just how important is this scientific paper?

The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene.
… READ MORE …

Time to death among men with nmCRPC by NCCN risk group

One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …